Supplementary Figure S1-S6 from Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow

Supplementary Figure S1-S6Supplementary Figure S1 shows tumor burden in the mice before BTZ treatment started (S1A), MM cell growth and apoptosis after co-cultured with BMS or pre-OBs of OB-Runx2-/- or OB-Runx2+/+ mice (S1B-F), and the proportion of PMN-MDSCs and M-MDSCs in the BM of Runx2-/- or OB-Runx2+/+ mice after 4-week treatment with BTZ (S1G-H).Supplementary Figure S2 shows tumor burden in the mice before SRI31277 and BTZ treatment (S2A) and the proportion of PMN-MDSCs and M-MDSCs in the BM of Runx2-/- or OB-Runx2+/+ mice after 4-week treatment with SRI31277 and BTZ (S2B-C).Supplementary Figure S3 shows tumor burden in the mice before 5-Fu and BTZ treatment.Supplementary Figure S4 shows the impact of GEM treatment on BTZ resistance of MM cells in OB-Runx2-/- mice.Supplementary Figure S5 shows the proportion of PMN-MDSCs and M-MDSCs in the BM of Runx2-/- or OB-Runx2+/+ mice after 4-week treatment with 5-Fu and BTZ.Supplementary Figure S6 shows the impact of GEM and BTZ treatment on MDSCs and CD8 T cells.